Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment
0 Views
administrator
07/06/23
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.
-
Category
Show more
Facebook Comments
No comments found